# A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

> **NCT01876251** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 30 (actual)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** PF-03084014
- **DRUG:** PF-03084014
- **DRUG:** PF-03084014
- **DRUG:** Docetaxel
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01876251
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11-04
- **Primary completion:** 2015-12-24
- **Final completion:** 2015-12-24
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development. There were no safety/efficacy concerns behind the decision.
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01876251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01876251, "A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01876251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*